Rebiotix Inc., part of the Ferring Pharmaceuticals Group, announced on 10/1/18 that data new from their Microbiota Restoration Therapy™ (MRT) drug development platform will be presented at the annual Infectious Disease conference, which will be held October 3-7 in San Francisco.

Each data set highlights the company’s continued leadership in the microbiome field, providing new insight into the durability of RBX2660 months after use as treatment in their recent Open-Label trial, to be presented by Rebiotix’s Associate Director of Clinical Research, Sarah Mische, PhD. Additionally, the company will share findings from the novel application of their Microbiome Health Index™, which has been developed as platform to quantify changes in patient microbiome profiles; Rebiotix’s Chief Scientific Officer, Ken Blount, PhD, will present the latest developments.

The titles of the presentations are:

• Prevention of Recurrent Clostridium difficile at Six Months following Treatment with Microbiota-based Therapy RBX2660: Durability Results from a Phase 2 Open-Label Study
• Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived from a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI)

RBX2660 is derived from human stool and includes spore and non-spore-forming microbes and is administered via ready-to-use enema. It has received FDA Fast Track, Breakthrough Therapy and Orphan Drug Designations.

To stay informed about developments in the Microbiome Arena, consider subscribing to CP Intel's microbiome database.